Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41577-020-00429-3 http://scihub22266oqcxt.onion/10.1038/s41577-020-00429-3 32788708!8824445!32788708     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Immunol 2020 ; 20 (10): 585-586 Nephropedia Template TP {{tp|p=32788708|t=2020. The type I interferon response in COVID-19: implications for treatment |pdf=|usr=}}{{32788708}} gab.com Text The type I interferon response in COVID-19: implications for treatment JO: Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32788708 #FOAvip Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19. Twit Text FOAVip The type I interferon response in COVID-19: implications for treatment ????Nat Rev Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32788708 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32788708 #FOAvip English Wikipedia <ref>{{Cite pmid|32788708}}</ref> The type I interferon response in COVID-19: implications for treatment #MMPMID32788708 Lee JS; Shin EC Nat Rev Immunol 2020[Oct]; 20 (10): 585-586 PMID32788708show ga Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19. |Azetidines/*therapeutic use[MESH] |Betacoronavirus/immunology/*pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/immunology/pathology/virology[MESH] |Gene Expression Regulation[MESH] |Humans[MESH] |Immunity, Cellular/drug effects[MESH] |Immunity, Humoral/drug effects[MESH] |Interferon Regulatory Factors/genetics/immunology[MESH] |Interferon-alpha/genetics/immunology/*therapeutic use[MESH] |Interferon-beta/genetics/immunology/*therapeutic use[MESH] |Interferons/genetics/immunology/*therapeutic use[MESH] |Interleukin-1/genetics/immunology[MESH] |Interleukin-6/antagonists & inhibitors/genetics/immunology[MESH] |Janus Kinase 1/antagonists & inhibitors/genetics/immunology[MESH] |Lung/drug effects/immunology/pathology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/immunology/pathology/virology[MESH] |Purines[MESH] |Pyrazoles[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Sulfonamides/*therapeutic use[MESH]The type I interferon response in COVID-19: implications for treatment(epmc).pdf DeepDyve Pubget Overpricing